Research programme: inflammatory bowel disease therapeutics - ViThera PharmaceuticalsAlternative Names: VT301; VT301 + elafin
Latest Information Update: 16 Jul 2016
At a glance
- Originator Unknown
- Developer ViThera Pharmaceuticals
- Class Bacteria; Recombinant proteins
- Mechanism of Action Bacteria replacements; Leucocyte elastase inhibitors; Myeloblastin inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Inflammatory bowel diseases
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammatory-bowel-disease in USA (PO)
- 31 Oct 2012 Preclinical trials in Inflammatory bowel disease in USA (PO)